Xilio Therapeutics (XLO) Interest Coverage Ratio Growth (1y) (2021 - 2026)
Xilio Therapeutics (XLO) Interest Coverage Ratio Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -60.78% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -25.59% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1,170.12% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 751.68% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 99.48% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -53.46% |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 92.65% |
| Mar 31, 2026 | -216.38% |
| Dec 31, 2025 | -807.04% |
| Sep 30, 2025 | 80.98% |
| Jun 30, 2025 | -338.40% |
| Mar 31, 2025 | -321.54% |
| Dec 31, 2024 | 39.75% |
| Sep 30, 2024 | 63.07% |
| Jun 30, 2024 | 67.84% |
| Mar 31, 2024 | 50.53% |
| Dec 31, 2023 | -334.23% |
| Sep 30, 2023 | -337.59% |
| Jun 30, 2023 | -190.49% |
| Mar 31, 2023 | -6.07% |
| Dec 31, 2022 | 90.55% |
| Sep 30, 2022 | -9,030.53% |
| Jun 30, 2022 | 58.56% |
| Mar 31, 2022 | -28.47% |
| Dec 31, 2021 | -14.90% |
| Sep 30, 2021 | 98.65% |